Northwestern University of Evanston, Ill., has received US Patent No. 7,954,166, "Independently-addressable, self-correcting inking for cantilever arrays." A method of loading tips and other surfaces with patterning compositions or inks for use in deposition is claimed. It includes providing at least one array of tips; providing the patterning compositions; ink jet printing the patterning compositions onto some of the tips; and depositing the patterning compositions onto a substrate surface. According to the patent, the ink jet printing is adapted to prevent cross-contamination of the patterning composition on the tips. The method can be used to produce high-density arrays.
Illumina of San Diego has received US Patent No. 7,955,794, "Multiplex nucleic acid reactions." A multiplex method for determining whether a sample contains at least 100 different target sequences is claimed. It includes providing a sample that may contain at least 100 different single-stranded target sequences attached to a first solid support; and contacting the target sequences with a probe set of more than 100 different single-stranded probes. According to the patent, each probe includes a universal priming site and a target-specific domain, so that different double-stranded hybridization complexes are formed. Unhybridized probes are then removed, and the hybridization complexes are contacted with a primer that hybridizes to the universal priming site, nucleoside triphosphates, and an extension enzyme. Different amplicons are subsequently formed that are hybridized to a second solid support and detected to determine whether the sample contains at least 100 different target sequences.
Roche Diagnostics of Indianapolis, Ind., has received US Patent No. 7,955,798, "Reusable substrate for DNA microarray production." An electrode array consisting of selectively addressable electrodes is provided, as well as a porous membrane containing binding sites for biopolymer building blocks. According to the patent, the binding sites bear protective groups that are electrochemically unstable. Liquid reagents consisting of monomeric, oligomeric, or polymeric biopolymer building blocks are also provided. The porous membrane is brought into physical contact with the electrode array, producing the biopolymer array, which is then removed from the electrode array.
Samsung Electronics of Seoul, Korea, has received US Patent No. 7,955,801, "Method and apparatus for disrupting cells and purifying nucleic acid using a single chip." The claimed method includes irradiating a biochip with a laser beam, where the chip consists of a solid support upon which a cell lysis enhancing metal oxide layer and a cell binding metal oxide layer have been deposited. More specifically, a cell-containing sample solution is introduced to the solid support, after which the cells bind with the metal oxide. The support is irradiated with a laser to disrupt the cells to release a nucleic acid that binds with the cell-binding metal oxide. A washing buffer is introduced to the solid support to wash the cell-containing sample solution that is not bound to the cell-binding metal oxide and a nucleic acid eluting buffer is introduced to the solid support to elute the nucleic acid bound to the cell-binding metal oxide.
Bayer Technology Services of Leverkusen, Germany, has received US Patent No. 7,955,837, "Process for determining one or more analytes in samples of biological origin having complex composition, and use thereof." A process for detecting one or more analytes in one or more samples of biological origin is claimed. A microarray for quantitative determination of analytes in the samples is also provided, where the samples are immobilized in measurement ranges of array.
The Institute of Cancer Research of London has received US Patent No. 7,956,011, "Materials and methods for the photodirected synthesis of oligonucleotide arrays." The methods employ a film formed from a photoacid generator that upon photolysis generates acid that is capable of directly removing the protecting group of the linker molecules or oligonucleotides, as well as a polymer substantially lacking electronegative heteroatoms that are capable of hydrogen bonding with photogenerated acid. According to the patent, the film restricts diffusion of reactants and products on the substrate during synthesis of the array and includes a precursor of a deprotecting reagent.
Harvard University of Cambridge, Mass., has received US Patent No. 7,956,427, "Nanosensors." The patent claims a device consisting of a semiconductor nanowire with a polymer material deposited on it, as well as a detector constructed and arranged to determine an electrical property associated with the semiconductor nanowire. According to the patent, the polymer material is capable of recognizing an analyte in a sample, and the semiconductor nanowire exhibits a detectable change in an electrical property when the analyte binds to the polymer material. Such semiconductor nanowires can form a number of nanowire sensors in a sensor array formed on a surface of a substrate.
New York University of New York has received US Patent No. 7,957,908, "System, method and software arrangement utilizing a multi-strip procedure that can be applied to gene characterization using DNA-array data." The method uses a fast adaptive multiscale procedure to characterize a random set of points spanning a high dimensional Euclidean space, and concentrated around special lower dimensional subsets. The procedure can be adapted to analyze gene expression data from microarray experiments, and may be applied generally to existing datasets without regard to whether a particular model exists to otherwise describe the dataset, according to the patent's abstract. The procedure can also be used for identifying and mathematically isolating stable sets of data points in a given dataset from those in the same dataset that deviate from a stable model under various conditions.
Population Diagnostics of Melville, NY, has received US Patent No. 7,957,913, "Evaluating genetic disorders." A method of determining whether a therapeutic is useful for treating a condition or disease is described. It involves screening a subject's genome with PCR, array comparative genomic hybridization, sequencing, SNP genotyping, or fluorescence in situ hybridization to provide information on one or more copy number variants; comparing the copy number variants from the genome of a subject to a compilation of data comprising frequencies of CNVs in at least 100 subjects; and determining the statistical significance of the CNV to the success or failure of a certain therapeutic to treat a condition or disease.